Background: Clinical consequences of an interplay between dysfunction/injury of different end-organs in acute heart failure (AHF) remain unknown.

Methods And Results: In 284 consecutive AHF patients, end-organ dysfunction/injury was defined as cardiac [troponin I level above the upper reference limit (URL, > 0.056 ng/mL)], kidney (estimated glomerular filtration rate < 60 mL/min/1.73 m ), and liver [at least one of the following: aspartate transaminase (AST)/alanine transaminase (ALT) > 3 times the URL (> 114 IU/L and > 105 IU/L for AST and ALT, respectively), bilirubin above the URL (> 1.3 mg/mL), albumin below the lower reference limit (< 3.5 mg/dL)]. The primary endpoints were early (within first 48 h) in-hospital worsening of heart failure and 1-year all-cause mortality. On admission, cardiac, kidney, liver dysfunction/injury were present in 38%, 50%, and 54% of patients, respectively. Patients were classified as having 0, 1, 2, or 3 organ injury/dysfunction (17%, 36%, 35%, and 12% of patients, respectively). Baseline clinical characteristics and co-morbidity profile were similar across groups. Patients with three organ dysfunction/injury had the worst 1-year survival rate [46%; hazard ratio (HR) with 95% confidence interval (CI) vs. patients without organ dysfunction: 6.75 (2.52-18.13), those with two (67%; HR 3.54, 95% CI 1.38-9.08), one (84%; HR 1.58, 95% CI 0.58-4.30), or no organ dysfunction/injury (90%); P < 0.01]. Worsening of heart failure was more frequent in patients with three and two vs. those with one or no organ dysfunction/injury (37% vs. 38% vs. 23% vs. 21%, P < 0.05).

Conclusions: In patients with AHF, dysfunction/injury of > 1 end-organ dysfunction/injury identifies patients at the highest risk of poor outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ejhf.1378DOI Listing

Publication Analysis

Top Keywords

acute heart
8
heart failure
8
reference limit
8
multi-organ dysfunction/injury
4
dysfunction/injury admission
4
admission identifies
4
identifies acute
4
failure patients
4
patients high
4
high risk
4

Similar Publications

Surgery in patients aged ≥ 80 years: mortality and recovery in a nationwide cohort study.

Anaesthesia

March 2025

Section of Anesthesiology and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Introduction: As the global population ages, the demand for surgical interventions in older adults is rising. Older patients face increased risks due to age-related physiological changes and comorbidities, making surgery and postoperative care challenging. This study aimed to assess short- and long-term mortality, as well as patient-centred outcomes such as days alive and at home 30 and 90 days after surgery, in patients aged ≥ 80 y undergoing surgical procedures.

View Article and Find Full Text PDF

Objectives: Accurately predicting short-term MACE (major adverse cardiac events) following primary percutaneous coronary intervention (PCI) remains a clinical challenge. This study aims to assess the effectiveness of four established risk scores in predicting short-term MACE after primary PCI.

Design: Prospective observational study.

View Article and Find Full Text PDF

Purpose/objective(s): Use of intensity-modulated radiation therapy (IMRT) versus three-dimensional conformal external beam radiation therapy (3D-CRT) for definitive chemoradiation therapy (CRT) in locally advanced non-small cell lung cancer (LA-NSCLC) has been associated with decreased late pneumonitis, decreased high dose to the heart (itself associated with improved overall survival), and improved patient quality of life. In a statewide radiation oncology quality consortium, we sought to evaluate the impact of IMRT versus 3D-CRT treatment technique on dosimetry and toxicity.

Materials/methods: From 2012 to 2022, 1746 LA-NSCLC patients meeting inclusion criteria underwent definitive RT (90% CRT) with either 3D-CRT (n=313) or IMRT (n=1433) and were enrolled in the [quality consortium] prospective, multicenter statewide initiative.

View Article and Find Full Text PDF

Background: Medtronic Micra VR and Abbott Aveir VR are two single-chamber ventricular leadless pacemakers (L-PMs) currently available in clinical practice. They differ in their design, fixation mechanism (tine-based fixation for Micra VR, screw-in helix fixation for Aveir VR), and implantation technique. Little comparative safety data are available for these LPMs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!